Compare DMLP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMLP | TYRA |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | DMLP | TYRA |
|---|---|---|
| Price | $25.52 | $30.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $38.83 |
| AVG Volume (30 Days) | 171.1K | ★ 646.3K |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $143,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.85 | $6.42 |
| 52 Week High | $32.47 | $32.44 |
| Indicator | DMLP | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 73.77 | 61.88 |
| Support Level | $23.35 | $28.51 |
| Resistance Level | $25.83 | $32.39 |
| Average True Range (ATR) | 0.60 | 1.93 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 87.33 | 63.99 |
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.